Emerging EZH2 Inhibitors and Their Application in Lymphoma
@article{Lue2018EmergingEI, title={Emerging EZH2 Inhibitors and Their Application in Lymphoma}, author={J. Lue and Jennifer E Amengual}, journal={Current Hematologic Malignancy Reports}, year={2018}, volume={13}, pages={369-382} }
Purpose of ReviewEnhancer of Zeste Homolog 2 (EZH2) is histone methyltransferase and catalyzes the methylation of histone 3 lysine 27, a mark of transcriptional repression. Various studies have elucidated the complex role of EZH2 in both normal biology and tumorigenesis. Here, we critically review the emerging role of EZH2 in malignancies, the development of small molecule inhibitors of EZH2, and their application in lymphoma.Recent FindingsActivating mutations and overexpression of EZH2 are… CONTINUE READING
29 Citations
EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
- Biology, Medicine
- Journal of Hematology & Oncology
- 2019
- 12
BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer
- Medicine
- Current Oncology Reports
- 2019
- 13
Deregulation of Polycomb Repressive Complex-2 in Mantle Cell Lymphoma Confers Growth Advantage by Epigenetic Suppression of cdkn2b
- Biology, Medicine
- Frontiers in Oncology
- 2020
- PDF
EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.
- Biology, Medicine
- Molecular immunology
- 2020
- 4
- PDF
Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
- Chemistry, Medicine
- Cancer letters
- 2020
Development of molecular intervention strategies for B-cell lymphoma
- Medicine
- Expert review of hematology
- 2020
EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma
- Biology, Medicine
- PloS one
- 2020
- PDF
β-TRCP-mediated AEBP2 ubiquitination and destruction controls cisplatin resistance in ovarian cancer.
- Biology, Medicine
- Biochemical and biophysical research communications
- 2019
- 4
References
SHOWING 1-10 OF 124 REFERENCES
Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.
- Medicine, Biology
- Chemistry & biology
- 2013
- 119
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- Biology, Medicine
- Nature
- 2012
- 1,297
Epigenetic Targeting with EZH2 and HDAC Inhibitors Is Synergistic in EZH2 Deregulated Lymphomas
- Chemistry
- 2016
- 3
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
- Biology, Medicine
- Proceedings of the National Academy of Sciences
- 2012
- 457
- PDF
EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies In Preclinical Models
- Business
- 2013
- 5
- PDF
Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.
- Medicine, Biology
- Blood
- 2015
- 149
- PDF
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- Biology, Medicine
- Molecular Cancer Therapeutics
- 2014
- 332
- PDF
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
- Biology, Medicine
- Nature chemical biology
- 2012
- 602
- PDF